Home > Insider Trading > Filing (0001209191-20-051590)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1510487	Principia Biopharma Inc.	PRNB	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1506218	C. Roy Hardiman	C/O Principia Biopharma Inc. 220 E. Grand Avenue South San Francisco CA 94080	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-09-18	2,758	$4.72	120,519	No	4	M	Direct
Common Stock	Acquisiton	2020-09-18	2,242	$7.27	122,761	No	4	M	Direct
Common Stock	Disposition	2020-09-18	5,000	$99.98	117,761	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2020-09-18	2,758	$0.00	2,758	$4.72
Common Stock	Employee Stock Option (right to buy)	Disposition	2020-09-18	2,242	$0.00	2,242	$7.27

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2025-02-25	No	4	M	Direct
11,519		2027-12-13	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,916	Indirect	See footnote

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
Represents the weighted average sales price per share. The shares sold at prices ranging from $99.95 to $100.05 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Shares indirectly held by Roy Hardiman, as a fiduciary for his child, of which the Reporting Person may be deemed to share voting and dispositive power over these shares.
The stock option is fully vested and immediately exercisable.
The stock option vested and became exercisable as to 25% of the shares subject to the option on December 14, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.